Expressive

rs1061170 (CFH): Age-Related Macular Degeneration Risk

Key takeaways

  • rs1061170 is one of the most strongly replicated genetic risk variants for advanced age-related macular degeneration, confirmed across studies of tens of thousands of patients
  • The minor allele (CFH-H402) impairs complement factor H's ability to bind malondialdehyde, an oxidative-damage marker that accumulates in aging retinal tissue
  • The variant is associated with reduced expression of related complement proteins CFHR1 and CFHR3 across liver, spleen, lung, thyroid, and other tissues
  • The CFH locus is one of the most genetically pleiotropic regions in the human proteome, linking to a vast number of plasma proteins
  • Impaired immune regulation of oxidized debris caused by this variant may explain its links to multiple complement-related diseases

Key takeaways

  • rs1061170 is one of the most strongly replicated genetic risk variants for advanced age-related macular degeneration, confirmed across studies of tens of thousands of patients
  • The minor allele (CFH-H402) impairs complement factor H's ability to bind malondialdehyde, an oxidative-damage marker that accumulates in aging retinal tissue
  • The variant is associated with reduced expression of related complement proteins CFHR1 and CFHR3 across liver, spleen, lung, thyroid, and other tissues
  • The CFH locus is one of the most genetically pleiotropic regions in the human proteome, linking to a vast number of plasma proteins
  • Impaired immune regulation of oxidized debris caused by this variant may explain its links to multiple complement-related diseases

What the research says In a genome-wide association study of 1,830 individuals, rs1061170 was identified as a dominant genetic variant modifying plasma CFH and its splice variant FHL-1 (factor H-like protein 1) binding to malondialdehyde (MDA)-epitopes - cellular markers of oxidative damage; the minor allele (CFH-H402, located in the seventh short consensus repeat domain, SCR7) impairs this binding and reduces CFH cofactor activity on MDA-modified surfaces, allowing enhanced complement activation PMID 33082228. This variant was confirmed at genome-wide significance for advanced AMD in a meta-analysis with discovery in 2,594 AMD cases and 4,134 controls, replicated in 5,640 cases and 52,174 controls PMID 21908519. The CFH locus displays exceptional pleiotropy: variants at this region associate with 59 to 1,539 distinct plasma protein targets in a proteome-wide study of 10,708 individuals PMID 34588244.

Reported associations

  • Advanced age-related macular degeneration: Confirmed at genome-wide significance in a meta-analysis of 2,594 cases and 4,134 controls with replication in 5,640 cases and 52,174 controls PMID 21908519
  • Advanced AMD (CNV vs. GA subtype analysis): Included in subtype-stratified GWAS of 2,594 cases and 4,134 controls with replication in 5,383 advanced AMD participants and 15,240 controls; both choroidal neovascularization (CNV) and geographic atrophy (GA) subtypes were examined PMID 22281395
  • Advanced AMD (multi-cohort confirmation): Recognized as an established AMD risk locus in a GWAS of 979 cases and 1,709 controls, replicated across seven additional cohorts totaling 5,789 cases and 4,234 controls PMID 20385826
  • CFH/FHL-1 binding to malondialdehyde (MDA)-epitopes: Identified as a dominant genetic modulator of plasma CFH's ability to bind MDA in a GWAS of 1,830 individuals; the minor allele reduces CFH and FHL-1 binding, diminishing complement regulatory activity on MDA-modified surfaces PMID 33082228
  • Plasma protein levels (proteome-wide pleiotropy): The CFH locus is among eight genomic regions showing the greatest proteome-wide pleiotropy, associating with 59 to 1,539 distinct plasma protein targets in a study of 10,708 individuals PMID 34588244

Evidence quality The AMD associations of rs1061170 are among the most consistently replicated findings in ophthalmic genetics. A large meta-analysis confirmed genome-wide significance with a combined total of approximately 8,234 AMD cases and 56,308 controls PMID 21908519; a subtype-stratified GWAS independently confirmed the locus across approximately 7,977 AMD cases and 19,374 controls PMID 22281395; and an earlier study confirmed it across approximately 6,768 cases and 5,943 controls in eight cohorts PMID 20385826. A focused mechanistic GWAS of 1,830 individuals established the functional link between this variant and impaired CFH-MDA binding PMID 33082228; this sample is considerably smaller than the AMD outcome studies. The proteome-wide pleiotropy evidence comes from 10,708 individuals PMID 34588244, though which specific variant(s) within the CFH locus drive proteomic effects cannot be fully resolved from the provided evidence. One mechanistic complexity is worth noting: the same study that identified rs1061170 as impairing CFH function also found that deletion of the related CFHR3 and CFHR1 genes is protective in AMD, because CFHR1 and CFHR3 proteins compete with CFH for MDA-epitope binding and displace it from damaged surfaces PMID 33082228; eQTL data show the alternative allele at this locus is also associated with reduced CFHR1 and CFHR3 expression across multiple tissues, which based on the functional evidence would represent a partially opposing protective mechanism. The net AMD outcome reflects both effects simultaneously.

Tissue-specific expression effects

  • CFHR1 (complement factor H-related protein 1): The alternative allele is associated with reduced expression in liver and spleen GTEx Portal
  • CFHR3 (complement factor H-related protein 3): The alternative allele is associated with reduced expression across six tissues - adrenal gland, visceral adipose tissue (omentum), thyroid, lung, heart atrial appendage, and tibial artery GTEx Portal

Lifestyle considerations No lifestyle considerations on file for this variant.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • Genetic risk for age-related macular degeneration High

    rs1061170 C allele carriers have 2.4 to 3.7-fold elevated age-related macular degeneration risk; ophthalmologist discussion enables personalized screening and prevention strategy

Lifestyle

  • Cigarette smoking Moderate

    Smoking is documented as environmental risk modifier for age-related macular degeneration; particularly important for rs1061170 C-allele carriers with elevated genetic risk

Screening

  • Comprehensive eye examination for early macular degeneration High

    rs1061170 C allele increases macular degeneration risk up to 3.7-fold; early detection through examination enables vision-preserving intervention

    Annual dilated eye examination; baseline optical coherence tomography if not already done

Frequently asked questions

What is rs1061170 and which gene does it affect?

rs1061170 is a common genetic variant in the complement factor H gene (CFH). The minor allele changes an amino acid in the seventh short consensus repeat (SCR7) domain of CFH, creating a form called CFH-H402 that binds less effectively to malondialdehyde, an oxidative-damage marker found on cell surfaces.

Is rs1061170 linked to age-related macular degeneration?

Yes. rs1061170 is one of the most consistently replicated genetic risk variants for advanced age-related macular degeneration (AMD), confirmed across multiple large genome-wide association studies and meta-analyses involving tens of thousands of participants across independent cohorts.

What does complement factor H (CFH) do in the body?

CFH is a major inhibitor of the alternative complement pathway, a branch of the innate immune system that destroys damaged or foreign cells. It acts as a molecular brake on complement activation, preventing excessive inflammation on healthy and damaged tissue surfaces by recognizing and regulating complement on self-structures.

Why does rs1061170 affect AMD risk?

The minor allele reduces CFH's ability to bind malondialdehyde (MDA), an oxidative-stress marker that accumulates in aging retinal tissue including drusen deposits. Reduced CFH binding means less complement regulation on MDA-decorated retinal surfaces, potentially allowing unchecked complement-driven inflammation in the eye.

Does rs1061170 affect gene expression beyond CFH itself?

Yes. Based on tissue expression data, the alternative allele at this locus is associated with reduced expression of CFHR1 in liver and spleen, and CFHR3 across multiple tissues including adrenal gland, thyroid, lung, and blood vessels, suggesting broad systemic effects on complement-related protein levels.